Healthcare Player Gujarat Kidney and Super Speciality to Launch IPO on December 22

Gujarat Kidney and Super Speciality Limited IPO to Open on December 22; Price Band Set at Rs 108–114

Ahmedabad, December 16, 2025:
Gujarat Kidney and Super Speciality Limited has announced the opening of its maiden Initial Public Offering (IPO), which will be available for subscription from Monday, December 22, 2025, to Wednesday, December 24, 2025. The company has fixed a price band of Rs 108 to Rs 114 per equity share, with a face value of Rs 2 each.

The IPO is a fresh issue of up to 2.20 crore equity shares, and investors can bid for a minimum lot size of 128 equity shares, and in multiples thereof. As on date, the company has 5,68,43,250 equity shares outstanding.

Gujarat Kidney and Super Speciality Limited is a regional healthcare provider operating a chain of mid-sized multispeciality hospitals across central Gujarat, with a strong focus on secondary and tertiary healthcare services. On a consolidated basis, the company operates seven multispeciality hospitals and four in-house pharmacies across Vadodara, Godhra, Bharuch, Borsad and Anand. Its hospital network has a total bed capacity of 490 beds, with 340 operational beds.

The company provides a comprehensive range of healthcare services, including secondary surgical services and tertiary super-speciality surgical procedures, supported by integrated diagnostic services and in-house pharmacies. It has strategically focused on under-penetrated healthcare markets in Gujarat, aiming to deliver quality and affordable healthcare while leveraging its understanding of regional patient needs and medical ecosystems.

For the financial year ended March 31, 2025, the company reported revenue from operations of Rs 40.24 crore and a net profit of Rs 9.49 crore. During the three-month period ended June 30, 2025, revenue stood at Rs 15.26 crore, while net profit was Rs 5.40 crore, reflecting improving operational performance.

The IPO is being made through the book-building route, with up to 75% of the net issue allocated to Qualified Institutional Buyers (QIBs), 15% to Non-Institutional Investors (NIIs), and 10% to Retail Individual Investors (RIIs).

Nirbhay Capital Services Private Limited is acting as the Book Running Lead Manager, while MUFG Intime India Limited has been appointed as the Registrar to the Issue.

Commenting on the IPO, Dr. Pragnesh Bharpoda, Chairman and Managing Director, along with the management team, shared the company’s growth vision and IPO details during a webinar organised on Tuesday.

IPO Snapshot: Gujarat Kidney and Super Speciality Limited